# Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy

> **NCT06907641** · PHASE2 · RECRUITING · sponsor: **St Vincent's Hospital, Sydney** · enrollment: 50 (estimated)

## Conditions studied

- Prostate Cancer (Post Prostatectomy)

## Interventions

- **DRUG:** 64Cu-SAR-bisPSMA

## Key facts

- **NCT ID:** NCT06907641
- **Lead sponsor:** St Vincent's Hospital, Sydney
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-21
- **Primary completion:** 2025-11
- **Final completion:** 2025-11
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06907641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06907641, "Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06907641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*